Grifols (GRFS) Receivables - Net (2009 - 2025)
Grifols (GRFS) posted Receivables - Net of $757.8 million for Q4 2025, up 0.59% quarter-over-quarter from $753.4 million in Q4 2024, and up 0.59% year-on-year from $753.4 million in Q4 2024.
Grifols (GRFS) Receivables - Net (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Receivables - Net for 16 consecutive years, with $757.8 million the latest figure, recorded in Q4 2025.
- Receivables - Net for Q4 2025 came in at $757.8 million, up 0.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $757.8 million (up 0.59% YoY), and the FY2025 annual result was $757.8 million, up 0.59% from the prior year.
- Receivables - Net was $757.8 million for Q4 2025 at Grifols, up from $753.4 million in the prior quarter.
- Over five years, Receivables - Net peaked at $757.8 million in Q4 2025 and troughed at $496.6 million in Q4 2021.
- Average Receivables - Net over 5 years is $701.5 million, with a median of $753.4 million recorded in 2024.
- Year-over-year, Receivables - Net jumped 51.82% in 2022 and declined 1.13% in 2023.
- Over 5 years, Receivables - Net stood at $496.6 million in 2021, then surged by 51.82% to $754.0 million in 2022, then dropped by 1.13% to $745.5 million in 2023, then grew by 1.06% to $753.4 million in 2024, then gained by 0.59% to $757.8 million in 2025.
- Per Business Quant data, the three most recent Receivables - Net figures were $757.8 million in Q4 2025, $753.4 million in Q4 2024, and $745.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 757.79 Mn |
| Dec 31, 2025 | 757.79 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2023 | 745.48 Mn |
| Dec 31, 2023 | 745.48 Mn |
| Dec 31, 2022 | 754.01 Mn |
| Dec 31, 2022 | 754.01 Mn |
| Dec 31, 2021 | 494.42 Mn |
| Dec 31, 2021 | 494.42 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Dec 31, 2017 | 336.98 Mn |
| Dec 31, 2017 | 336.98 Mn |